Distinct functional classes of PDGFRB pathogenic variants in primary familial brain calcification

S Lenglez, A Sablon, G Fénelon… - Human molecular …, 2022 - academic.oup.com
S Lenglez, A Sablon, G Fénelon, A Boland, JF Deleuze, C Boutoleau-Bretonnière, G Nicolas
Human molecular genetics, 2022academic.oup.com
Platelet-derived growth factor receptor beta (PDGFRB) is one of the genes associated with
primary familial brain calcification (PFBC), an inherited neurological disease (OMIM:
173410). Genetic analysis of patients and families revealed at least 13 PDGFRB
heterozygous missense variants, including two novel ones described in the present report.
Limited experimental data published on five of these variants had suggested that they
decrease the receptor activity. No functional information was available on the impact of …
Abstract
Platelet-derived growth factor receptor beta (PDGFRB) is one of the genes associated with primary familial brain calcification (PFBC), an inherited neurological disease (OMIM:173410). Genetic analysis of patients and families revealed at least 13 PDGFRB heterozygous missense variants, including two novel ones described in the present report. Limited experimental data published on five of these variants had suggested that they decrease the receptor activity. No functional information was available on the impact of variants located within the receptor extracellular domains. Here, we performed a comprehensive molecular analysis of PDGFRB variants linked to PFBC. Mutated receptors were transfected in various cell lines to monitor receptor expression, signaling, mitogenic activity and ligand binding. Four mutants caused a complete loss of tyrosine kinase activity in multiple assays. One of the novel variants, p.Pro154Ser, decreased the receptor expression and abolished binding of platelet-derived growth factor (PDGF-BB). Others showed a partial loss of function related to reduced expression or signaling. Combining clinical, genetic and molecular data, we consider nine variants as pathogenic or likely pathogenic, three as benign or likely benign and one as a variant of unknown significance. We discuss the possible relationship between the variant residual activity, incomplete penetrance, brain calcification and neurological symptoms. In conclusion, we identified distinct molecular mechanisms whereby PDGFRB variants may result in a receptor loss of function. This work will facilitate genetic counseling in PFBC.
Oxford University Press